AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02198742 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glidescope Cobolt
Description: Subjects were required to watch a instructional video provided by the manufacturer. Subjects were then allowed to practice on a normal model until they felt comfortable before beginning the study. There is no placebo group, and each subject wil be his or her own control.
Study NCT03053323 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: The lifestyle intervention consists of three components: nutrition, physical activity, and other areas of wellness. The intervention is administered individually each week for 10 weeks and is tailored for women with a history of depression who are in the first trimester of pregnancy or trying to conceive.
Study NCT02710422 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sexual History Inventory for Men
Description: SHIM psychosocial questionnaire administered at baseline, and post-RARP at protocol-defined intervals.
Study NCT02710422 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Sexual History Inventory for Men
Description: SHIM psychosocial questionnaire administered at baseline, and post-RARP at protocol-defined intervals.
Study NCT02552199 — intervention group
Intervention type: OTHER
Intervention: gravimetric
Study NCT01760707 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise training
Study NCT01760707 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Study NCT00754819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: 1mg once daily
Study NCT00754819 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule daily
Study NCT04610840 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Puncture of the caliceal system
Description: Puncture of the caliceal system under ultrasound/Xray control
Study NCT01806545 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SRM003
Description: One time implant (2 SRM003 pieces) on surgery day.
Study NCT01806545 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Participating Site's standard practice
Description: Subjects will receive sites' standard practice treatment during the surgical procedure.
Study NCT02116907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2007
Description: 14C-labeled perampanel dissolved in ethanol and administered using a capsule formulation in a single dose, one day
Study NCT00281528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-007 (Abraxane)
Description: 30 minute infusions
Study NCT00281528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: infusions
Study NCT04590430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HFB30132A
Description: Participants randomized to HFB30132A will be administered dose 1 in cohort 1. Participants in Cohort 2 and 3 will receive HFB30132A doses 2 and 3, respectively.
Study NCT04590430 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to placebo will receive the same volume of solution as participants on active treatment.
Study NCT02709460 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateral occlusion
Description: Lateral occlusion close to the internal Iliac artery
Study NCT03502590 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IGEL Laryngeal mask
Description: Insertion of an IGEL device in anaesthetised patients
Study NCT03495960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: PART A - INDUCTION PHASE During the primary chemo-immunotherapy (PRIMAIN regimen, 2 courses; every 43 days) administered as induction in the PART A of the study, Rituximab is given 375 mg/m2 as standard infusion at days -6, 1, 15 \& 29. Rituximab on day -6 will be delivered only during the first course; it will be delivered between day -6 and day 0 according to clinical requirements and patient's conditions. Some patients would need for a fast chemotherapy starting.~PART B - INDUCTION PHASE Patients ineligible for high-dose methotrexate, will be assigned to receive concomitant whole brain radiotherapy-temozolomide-rituximab (Induction Part B). Rituximab is given 375 mg/m2 in 4 weekly doses, starting on day 2 of radiotherapy.
Study NCT03495960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: PART A - INDUCTION PHASE During the primary chemo-immunotherapy (PRIMAIN regimen, 2 courses; every 43 days) administered as induction in the PART A of the study, Rituximab is given 375 mg/m2 as standard infusion at days -6, 1, 15 \& 29. Rituximab on day -6 will be delivered only during the first course; it will be delivered between day -6 and day 0 according to clinical requirements and patient's conditions. Some patients would need for a fast chemotherapy starting.~PART B - INDUCTION PHASE Patients ineligible for high-dose methotrexate, will be assigned to receive concomitant whole brain radiotherapy-temozolomide-rituximab (Induction Part B). Rituximab is given 375 mg/m2 in 4 weekly doses, starting on day 2 of radiotherapy.
Study NCT03495960 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rituximab
Description: PART A - INDUCTION PHASE During the primary chemo-immunotherapy (PRIMAIN regimen, 2 courses; every 43 days) administered as induction in the PART A of the study, Rituximab is given 375 mg/m2 as standard infusion at days -6, 1, 15 \& 29. Rituximab on day -6 will be delivered only during the first course; it will be delivered between day -6 and day 0 according to clinical requirements and patient's conditions. Some patients would need for a fast chemotherapy starting.~PART B - INDUCTION PHASE Patients ineligible for high-dose methotrexate, will be assigned to receive concomitant whole brain radiotherapy-temozolomide-rituximab (Induction Part B). Rituximab is given 375 mg/m2 in 4 weekly doses, starting on day 2 of radiotherapy.
Study NCT02709460 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical occlusion
Description: Cervical occlusion of the uterine artery
Study NCT02903225 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Rehabilitation
Description: All patients included in this group attended a supervised exercise training program. A cardiologist supervised the hole training sessions. Blood pressure, pulse rate, oxygen saturation, and body weight were measured in each session. The modified Borg scale was used to measure the perceived exercise intensity
Study NCT01601106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liposomal prednisolone
Description: Two weekly dosages with 150 mg.
Study NCT01601106 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: liposomal prednisolone
Description: Two weekly dosages with 150 mg.
Study NCT01601106 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02957422 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1% Milk
Description: 1.5 gallons of 1% milk will be delivered to the participant's home weekly. Participants will be asked to drink 3 cups per day for 3 months.
Study NCT02957422 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants will continue on their regular low dairy diet of ≤1.5 dairy serving/day.
Study NCT02272491 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZrO2 (Straumann CARES)
Description: 1. Straumann CARES Variobase Abutment RN~2. Straumann CARES Full Contour Zerion HT The monolithic zircona crown (2) will be bonded to the titanium base (1)
Study NCT02272491 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PFM crown (Straumann Gold)
Description: Porcelain-fused-to-metal crown consisting of a gold abutment, a gold core, and veneering ceramic
Study NCT01508650 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care control group
Study NCT01508650 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation intervention
Description: Multi-domain rehabilitation intervention
Study NCT04165434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concurrent Training
Description: Strength training and interval aerobic training in the same training session
Study NCT03258151 — intervention group
Intervention type: GENETIC
Intervention: detection of genotype
Description: detection of genotype by next generation sequencing
Study NCT03095014 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cesarean Myomectomy
Description: Myomectomy was done during Cesarean section
Study NCT03095014 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cesarean section
Description: Cesarean delivery
Study NCT01851616 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 25g of glucose in 200ml tap water, given orally (plus 50 mg 13C-sodium acetate)
Study NCT01851616 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 10g Glucose in 200ml tap water given orally (plus 50 mg 13C-sodium acetate)
Study NCT01463878 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glycerna
Description: Diabetes specific formula
Study NCT01463878 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Jevity - Control Diet
Description: Control Diet
Study NCT04376372 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Functional testing, Magnetic resonance imaging, Electromyography
Description: Electromyography only for cases (F-Lefthanders), not for controls (TD-lefthanders)
Study NCT00085631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00085631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: Given IV
Study NCT00085631 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hyperthermia treatment
Description: Patients undergo hyperthermia treatment over 60-90 minutes
Study NCT00085631 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Description: Patients undergo brachytherapy for 2-3 days
Study NCT00085631 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: brachytherapy
Description: Patients undergo brachytherapy for 2-3 days
Study NCT00085631 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beam radiation therapy
Description: Patients undergo external beam radiation therapy once daily on days 1-5
Study NCT00085631 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: external beam radiation therapy
Description: Patients undergo external beam radiation therapy once daily on days 1-5
Study NCT01788332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olaparib
Description: Olaparib is a potent inhibitor of poly (ADP-ribose) polymerase enzyme (PARP), (molecular weight 434) that is being developed as a monotherapy as well as for combination with chemotherapy and other anti-cancer agents. Olaparib can lead to tumour regression in patients with DNA repair deficient NSCLC. Olaparib may also enhance the DNA damaging effects of chemotherapy.
Study NCT01788332 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 100mg tablets to be administered twice a day with approximately 240ml of water
Study NCT03571815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% sodium fluoride varnish
Description: application of sodium fluoride varnish on teeth
Study NCT03571815 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: WATER ON TEETH
Description: control group
Study NCT02058667 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Paclitaxel+Initial Radiation+Boost
Description: Paclitaxel twice weekly + Initial Fields Radiation + Boost Radiation (10Gy)
Study NCT04404374 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: A-PRF/EMD
Description: Comparing healing effect of an autologous and a xenogenic product
Study NCT00545194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prostaglandin E2
Study NCT02692703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glecaprevir/pibrentasvir
Description: Tablet; glecaprevir coformulated with pibrentasvir
Study NCT04779840 — intervention group
Intervention type: OTHER
Intervention: anemia assessment
Description: evaluation of anemia status
Study NCT00495339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: 500-1000 mg once a day daily per os with combination of drugs.
Study NCT01925053 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PAL meal
Description: The effect of consuming the PAL meal on gastric retention will be assessed
Study NCT01925053 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: REF meal
Description: The effect of consuming the REF meal on gastric retention will be assessed
Study NCT00321802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Patients take 40 mg of simvastatin per day for 6 months.
Study NCT00321802 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00025766 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCI with stenting
Description: PCI with stenting of the occluded culprit infarct-related artery
Study NCT00025766 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Optimal Medical Therapy
Description: Participants will receive optimal medical therapy.
Study NCT00025766 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Medical Therapy
Description: Participants will receive optimal medical therapy.
Study NCT02170298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine
Description: Participants will be given either the study drug or placebo in tablet form. All participants will start with a 20 mg dose and will be titrated up to a 70 mg daily dose over 9 weeks. Participants between 12-18 years of age will be titrated in 10 mg increments and participants between 18-25 years of age in 10-20 mg increments.
Study NCT02170298 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lisdexamfetamine
Description: Participants will be given either the study drug or placebo in tablet form. All participants will start with a 20 mg dose and will be titrated up to a 70 mg daily dose over 9 weeks. Participants between 12-18 years of age will be titrated in 10 mg increments and participants between 18-25 years of age in 10-20 mg increments.
Study NCT03414814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib 80 MG [Tagrisso]
Description: Osimertinib 80mg once daily until disease progression
Study NCT04107194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole 40mg
Description: Proton pump inhibitor
Study NCT04107194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40mg
Description: Proton pump inhibitor
Study NCT04107194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin 1000 MG
Description: Antibiotic
Study NCT04107194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin 1000 MG
Description: Antibiotic
Study NCT04107194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin 500mg
Description: Antibiotic
Study NCT04107194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500mg
Description: Antibiotic
Study NCT04107194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Antibiotic
Study NCT04107194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Antibiotic
Study NCT04107194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline 125 MG
Description: Antibiotic
Study NCT04107194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracycline 125 MG
Description: Antibiotic
Study NCT04107194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth Subcitrate
Description: Antibiotic adjuvant
Study NCT01216709 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ferrous sulfate
Description: 6.3 mg iron from iron drops and 0.3 mg iron from infant formula with no added iron (0.5 mg iron/L) for 45 days
Study NCT01216709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iron-fortified infant formula (12.4 mg iron/L)
Description: 6.6 mg iron from iron-fortified infant formula (12.4 mg iron/L) for 45 days
Study NCT01216709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iron-fortified infant formula (2.3 mg iron/L)
Description: 1.2 mg iron from iron-fortified infant formula (2.3 mg iron/L) for 45 days
Study NCT01343186 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Peginterferon alfa
Description: s,c, 45mcg of Ypeginterferon alfa-2a
Study NCT01343186 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Peginterferon alfa 2a
Description: s,c, 90mcg of Ypeginterferon alfa-2a or 180mcg of Pegasys.
Study NCT01343186 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Peginterferon alfa-2a
Description: s,c, 180mcg of Ypeginterferon alfa-2a or 180mcg of Pegasys.
Study NCT01343186 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Peginterferon alfa-2a
Description: s,c, 270mcg of Ypeginterferon alfa-2a or 180mcg of Pegasys.
Study NCT03299205 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The exercise intervention consists of moderate intensity aerobic exercise intervention that will include the wearing of an accelerometer (i.e. Fitbit Zip) to monitor daily activity and steps. Aerobic exercise will be conducted over 10-weeks in PLWHA +/- AUD. The programs will consist of aerobic exercise 3 days per week of moderate intensity for 30-45 minutes each session with the goal of achieving 135 minutes per week. The program will begin at low-moderate intensity and progress to higher intensity exercise after week 4 of the program. All exercise will be completed on a treadmill and supervised by study staff. Each participant will be provided with a Fitbit Zip to monitor daily activity and steps with a goal of 7000 steps per day.
Study NCT04107194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth Subcitrate
Description: Antibiotic adjuvant
Study NCT04107194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin 150 MG
Description: Antibiotic
Study NCT04107194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500mg
Description: Antibiotic
Study NCT05346926 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D-printed cast
Description: The 3D-printed casts are produced using 3D print technology based on software by Belgian software company: The patient's forearm is scanned with a tablet (duration: approx. 5 min), whereupon the cast is printed overnight according to the scan (duration: approx. 4h) and adjusted to the patient during the next appointment.
Study NCT05346926 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional cast
Description: A conventional plaster cast is applied for treatment of the distal radius fracture.
Study NCT03651830 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prosthetic Foot Emulator
Description: Participants will walk in the laboratory with the Prosthetic Foot Emulator (PFE) in three foot modes corresponding to actual study feet. Walking conditions will include self-selected speed, slow speed, fast speed, incline, and up stairs.
Study NCT03651830 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available prosthetic feet
Description: Participants will walk in the laboratory with three different commercially available prosthetic feet. Walking conditions will include self-selected speed, slow speed, fast speed, incline, and up stairs.~Additionally, participants will be fit with one of the actual feet and wear it at home and in the community for approximately two weeks. This will be followed by two-week periods in the community with each of the other two commercially available prosthetic feet.
Study NCT03501316 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hand Instrumentation Treatment
Description: Provision of treatment for periodontal disease using hand instrumentation. Following this, data will be collected relating to various factors, principle of which being systemic immune response.
Study NCT03501316 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonic Instrumentation Treatment
Description: Provision of treatment for periodontal disease using ultrasonic instrumentation. Following this, data will be collected relating to various factors, principle of which being systemic immune response.
Study NCT02944968 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THERMOCOOL SMARTTOUCH® SF-5D catheter
Study NCT02315001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: GLP-1 receptor agonist administered via subcutaneous injection
Study NCT02315001 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Volume-matched normal saline placebo administered via subcutaneous injection
Study NCT03071770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivosidenib (AG-120)
Description: A single-dose of ivosidenib (AG-120) administered in healthy Japanese and Caucasian subjects